一项名为“ASAP（尽可能快）”的试验对国际治疗标准提出了新的见解：对于急性髓系白血病（Acute Myeloid Leukemia, AML）患者，高剂量化疗并非移植前的必要步骤，这意味着患者可以更快地进行移植 [1]。

SELLAS 总裁兼首席执行官 Angelos Stergiou 医学博士、理学博士表示：“继上个月获得儿童急性淋巴细胞白血病认定之后，我们再次获得儿科罕见病认定，这是对 SLS009 改善患者（包括 AML 儿童）生活的全新转化治疗潜力的又一认可。

IDH1 mutations in MDS are crucial for guiding therapy decisions, offering one of the few targetable mutations in this disease ...

Study’s Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial ...

A systematic review finds AML patients receiving anthracycline remission induction therapy face a significant heart failure ...

Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...

Researchers used an 8-protein prognostic score termed the leukemia inflammatory risk score (LIRS) to identify inflammatory proteins with newly diagnosed AML.

CERo Therapeutics (CERO) announces it has concluded the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid ...

Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across ...

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20. On September 19, Syndax Pharmaceuticals ...